| Identification | More | [Name]
10-Hydroxycamptothecin | [CAS]
19685-09-7 | [Synonyms]
10-HYDROXYCAMPTOTHECIN
(+/-)-4-ethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
CAMPTOTHECIN, 10-HYDROXY-
CAMPTOTHECIN, 10-HYDROXY-, CAMPTOTHECA ACUMINATA
HCPT
HYDROXYCAMPTOTHECIN
HYDROXYCAMPTOTHECIN, 10-
(S)-10-HYDROXYCAMPTOTHECIN
SN38
(s)-10-hydroxycamptothecinhydrate
4’:6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione,4-ethyl-4,9-1h-pyrano(3
4’:6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione,4-ethyl-4,9-dihydroxy-,hydrate,(s)-1h-pyrano(3
hydrate,(s)-dihydroxy
hydroxy-camptotheci
Hydroxycamptothencine
(20S)-10-HYDROXYCAMPTOTHECIN 98%
(20S)-10-Hydroxycamptothecin
HYDROCAMPTOTHECINE
CAMPTOTHECIN, 10-HYDROXY(SH)
HYDROXYCAMPTOTHECIN, 10-(P) | [EINECS(EC#)]
805-668-4 | [Molecular Formula]
C20H16N2O5 | [MDL Number]
MFCD00189425 | [Molecular Weight]
364.35 | [MOL File]
19685-09-7.mol |
| Chemical Properties | Back Directory | [Appearance]
Yellow Solid | [Melting point ]
265-270°C | [Boiling point ]
820.7±65.0 °C(Predicted) | [density ]
1.60 | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
≥23.8 mg/mL in DMSO with gentle warming; insoluble in EtOH; insoluble in H2O | [form ]
powder to crystal | [pka]
8.93±0.40(Predicted) | [color ]
White to Yellow to Orange | [Usage]
A Camptothecin derivative; a topoisomerase inhibitor for cancer therapy | [InChIKey]
HAWSQZCWOQZXHI-FQEVSTJZSA-N | [CAS DataBase Reference]
19685-09-7(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
DNA topoisomerases relax supercoiled DNA during replication, transcription, recombination, repair, and chromosome condensation. The relaxation of DNA supercoiling by topoisomerase I at single-strand breaks represents a target for anticancer agents to intercalate between DNA base pairs, leading to the activation of apoptotic and cell cycle arrest pathways.1 (S)-10-hydroxy-Camptothecin is an inhibitor of topoisomerase I originally isolated from the Chinese tree C. acuminata. It is a member of the camptothecin family that demonstrates less toxicity than its parent compound.2 (S)-10-hydroxy-Camptothecin has strong anti-tumor activity against a wide range of experimental tumors including L1210 leukemia cells (IC50 = 1.15 μM).2 In vitro treatment of human HepG2 cells with 5-20 μM (S)-10-hydroxy-camptothecin results in cell cycle arrest at the G2/M phase.3 | [Chemical Properties]
Yellow Solid | [Uses]
A Camptothecin derivative; a topoisomerase inhibitor for cancer therapy | [Definition]
ChEBI: 10-Hydroxycamptothecin is a pyranoindolizinoquinoline. | [in vitro]
10-Hydroxycamptothecin inhibited the growth of BT-20 and MDA-231 cells with IC50 of 34.3nM and 7.27nM, respectively, which was more potent than camptothecin (CPT) with IC50>500nM. 10-Hydroxycamptothecin potently induces the formation of the pBR322 plasmid DNA cleavage complex mediated by human topoisomerase I with an EC50 of 0.35 μM, more than 50-fold more potent than CPT with an EC50 of 18.85 μM. 10-Hydroxycamptothecin treatment caused dose-dependent growth inhibition of human microvascular endothelial cells (HMECs) with IC50 of 0.31 μM and significantly inhibited HMEC migration with IC50 of 0.63 μM. Treatment of HMEC cells with 10-Hydroxycamptothecin also inhibited microtubule formation in a dose-dependent manner with IC50 of 0.96 μM. 10-Hydroxycamptothecin (5-20 nM) significantly inhibits the differentiation of Colo205 cells, arrests the cell cycle in G2 phase, and induces apoptosis through a caspase-3-dependent pathway. | [in vivo]
In the CAM model, 10-Hydroxycamptothecin treatment inhibited angiogenesis in a concentration-dependent manner, with 95% inhibition at 25 nM, more potent than suramin, which inhibited only 60% of angiogenesis at 125 nM. 10-Hydroxycamptothecin, administered orally at low doses of 2.5-7.5 mg/kg every two days, caused significant growth inhibition in Colo205 xenograft mice, but no acute toxicity. LD50: 104 mg/kg in mice (intraperitoneal injection). | [IC 50]
0.31 μm | [References]
[1] vladu b, woynarowski jm, manikumar g, wani mc, wall me, von hoff dd, wadkins rm. 7- and 10-substituted camptothecins: dependence of topoisomerase i-dna cleavable complex formation and stability on the 7- and 10-substituents. mol pharmacol. 2000 feb;57(2):243-51.
[2] xiao d, tan w, li m, ding j. antiangiogenic potential of 10-hydroxycamptothecin. life sci. 2001 aug 24;69(14):1619-28.
[3] ping yh, lee hc, lee jy, wu ph, ho lk, chi cw, lu mf, wang jj. anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. oncol rep. 2006 may;15(5):1273-9. |
|
|